Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen plus /- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor plus GnRHa in male breast cancer patients

ANNALS OF ONCOLOGY(2018)

Cited 4|Views20
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined